Vaccination and Antivirals Key to Preventing Severe Varicella-Zoster Virus Complications: Study

Therefore, the researchers conducted a comprehensive narrative review of major medical databases to evaluate pediatric symptoms and novel treatments across English, French, and German literature. As a broad review rather than a clinical trial, the study focused on synthesizing global data instead of relying on specific sample sizes or rigid endpoints.

Key Clinical Findings of the Review Includes:

• Childhood Incidence: Reviewers noted that pediatric HZ remains exceptionally rare in clinical settings, presenting with a calculated disease incidence of just 0.45 documented cases per 1,000 children under the age of 14 years.

• Severe Complications: Researchers highlighted that systemic viral manifestations carry severe clinical consequences, with neonatal varicella pneumonitis exhibiting an alarming mortality rate of up to 30% in acutely infected infants under six months of age.

• Vaccination Efficacy: Investigators found that widespread vaccine implementation drastically reduces circulating viral burdens, successfully cutting neurologic complication incidences from 2.8 down to 1.2 per 100,000 children and decreasing overall HZ rates by 75%.

• Treatment Windows: Scientists emphasized that administering intravenous acyclovir—the highly recommended gold standard therapy—within a strict 72-hour window of a cutaneous eruption is imperative for mitigating dangerous cerebrovascular complications and persistent post-herpetic neuralgia.

The results suggest that while pediatric VZV infections are frequently characterized by mild symptoms, the substantial viral infectivity and potential for up to 30% mortality in specific neonatal complications mandate vigilant primary prevention and rapid therapeutic action. Furthermore, executing prompt clinical management strategies within a 72-hour window is absolutely paramount for successfully mitigating severe disease outcomes and nerve damage in high-risk youths.

Thus, the review concludes for healthcare providers, these updated clinical insights gently underscore the ongoing importance of prioritizing routine hygiene measures, advocating for widespread pediatric vaccination schedules, and carefully deploying targeted antiviral therapies to safely protect immunocompromised or severely affected young patients.

Acknowledging that the long-term waning rate of vaccine-induced viral immunity currently remains relatively unknown, there appears to be a subtle need for continued longitudinal monitoring and further proactive exploration into emerging preventative clinical options, such as new adenovirus-vectored vaccines.

Reference

Wollina U, Chiriac AE, Chiriac A. Update on infection with varicella-zoster virus in children: A narrative review. Indian J Paediatr Dermatol 2025;26:1-9.